RGEN
Price
$172.81Alerts
Change
-$1.18 (-0.68%)
Updated
Nov 11, 03:27 PM (EDT)
Capitalization
9.79B
105 days until earnings call
Intraday BUY SELL Signals
WST
Price
$413.55Alerts
Change
+$1.00 (+0.24%)
Updated
Nov 11, 03:33 PM (EDT)
Capitalization
28.14B
99 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RGEN vs WST

RGEN vs WST Comparison Chart in %
View a ticker or compare two or three
VS
RGEN vs. WST commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGEN is a Hold and WST is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RGEN with price predictions
Nov 10, 2026

RGEN in downward trend: price dove below 50-day moving average on November 10, 2026

RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 38 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 57 cases where RGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 65 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for WST with price predictions
Nov 10, 2026

WST sees its Stochastic Oscillator ascending out of oversold territory

On November 10, 2026, the Stochastic Oscillator for WST moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In 45 of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on WST as a result. In 59 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

Following a +5.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where WST advanced for three days, in 200 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 147 of 228 cases where WST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.

Bearish Trend Analysis

The 10-day RSI Indicator for WST moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 25 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.

The Moving Average Convergence Divergence Histogram (MACD) for WST turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 30 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

WST broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. WST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.410) is normal, around the industry mean (4.964). P/E Ratio (50.802) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (2.925) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.005) among similar stocks. P/S Ratio (7.862) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
RGEN vs WST: Fundamental Ratings
RGEN
WST
OUTLOOK RATING
1..100
7113
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
8848
PRICE GROWTH RATING
1..100
397
P/E GROWTH RATING
1..100
9717
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WST's Valuation (84) in the Medical Specialties industry is in the same range as RGEN (99) in the Biotechnology industry. This means that WST’s stock grew similarly to RGEN’s over the last 12 months.

WST's Profit vs Risk Rating (95) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that WST’s stock grew similarly to RGEN’s over the last 12 months.

WST's SMR Rating (48) in the Medical Specialties industry is somewhat better than the same rating for RGEN (88) in the Biotechnology industry. This means that WST’s stock grew somewhat faster than RGEN’s over the last 12 months.

WST's Price Growth Rating (7) in the Medical Specialties industry is in the same range as RGEN (39) in the Biotechnology industry. This means that WST’s stock grew similarly to RGEN’s over the last 12 months.

WST's P/E Growth Rating (17) in the Medical Specialties industry is significantly better than the same rating for RGEN (97) in the Biotechnology industry. This means that WST’s stock grew significantly faster than RGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGENWST
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
63%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
65%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
68%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 9 days ago
57%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
58%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
64%
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (RGEN: $173.98 vs. WST: $412.55)
Brand notoriety: RGEN and WST are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: RGEN: 59% vs. WST: 64%
Market capitalization -- RGEN: $9.79B vs. WST: $28.14B
RGEN [@Pharmaceuticals: Other] is valued at $9.79B. WST’s [@Pharmaceuticals: Other] market capitalization is $28.14B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGEN’s FA Score shows that 0 FA rating(s) are green while WST’s FA Score has 2 green FA rating(s).

  • RGEN’s FA Score: 0 green, 5 red.
  • WST’s FA Score: 2 green, 3 red.
According to our system of comparison, WST is a better buy in the long-term than RGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGEN’s TA Score shows that 3 TA indicator(s) are bullish while WST’s TA Score has 4 bullish TA indicator(s).

  • RGEN’s TA Score: 3 bullish, 5 bearish.
  • WST’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, WST is a better buy in the short-term than RGEN.

Price Growth

RGEN (@Pharmaceuticals: Other) experienced а -2.41% price change this week, while WST (@Pharmaceuticals: Other) price change was +1.43% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.01%. For the same industry, the average monthly price growth was +6.28%, and the average quarterly price growth was +22.46%.

Reported Earning Dates

RGEN is expected to report earnings on Feb 24, 2027.

WST is expected to report earnings on Feb 18, 2027.

Industries' Descriptions

@Pharmaceuticals: Other (+2.01% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

RGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
-2.77%
DHR - RGEN
67%
Closely correlated
+0.42%
A - RGEN
65%
Loosely correlated
-1.27%
BIO - RGEN
60%
Loosely correlated
-0.47%
MTD - RGEN
59%
Loosely correlated
-0.62%
TMO - RGEN
58%
Loosely correlated
-0.48%
More

WST and

Correlation & Price change

A.I.dvisor indicates that over the last year, WST has been loosely correlated with STVN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if WST jumps, then STVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WST
1D Price
Change %
WST100%
-0.07%
STVN - WST
38%
Loosely correlated
-1.46%
RGEN - WST
34%
Loosely correlated
-2.77%
NVST - WST
34%
Loosely correlated
-0.50%
QDEL - WST
33%
Loosely correlated
-4.71%
CAPN - WST
32%
Poorly correlated
-0.18%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LOPP36.48N/A
N/A
Gabelli Love Our Planet & People ETF (LOPP)
CGDV48.48-0.03
-0.06%
Capital Group Dividend Value ETF (CGDV)
HTAB18.57-0.08
-0.43%
Hartford Schroders Tax-Aware Bond ETF (HTAB)
XVV57.08-0.34
-0.59%
iShares ESG Select Screened S&P 500 ETF (XVV)
OVF29.63-0.21
-0.71%
Overlay Shares Foreign Equity ETF (OVF)